MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

MDT

88.44

-1.53%↓

VEEV

227.74

-1.64%↓

A

113.65

-2.76%↓

HQY

87.08

-1.46%↓

PDCO

31.26

0%↓

Search

Aclaris Therapeutics Inc

Suletud

1.49 -2.61

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.45

Max

1.52

Põhinäitajad

By Trading Economics

Sissetulek

-89M

-97M

Müük

4.9M

9.2M

Aktsiakasum

-1.01

Kasumimarginaal

-1,048.225

Töötajad

61

EBITDA

-4.4M

-14M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+504.58% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

6. mai 2025

Turustatistika

By TradingEconomics

Turukapital

-37M

173M

Eelmine avamishind

4.1

Eelmine sulgemishind

1.49

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

Aclaris Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

16. juuli 2024, 20:04 UTC

Omandamised, ülevõtmised, äriostud

Aclaris Therapeutics Received $26.5 M Upfront Plus Is Eligible for Up to $5M in Milestones >ACRS

16. juuli 2024, 20:03 UTC

Omandamised, ülevõtmised, äriostud

Aclaris Sells Portion of Future Royalty Payments and Milestones From Eli Lilly on Sales of OLUMIANT for Alopecia Areata to OMERS

Võrdlus sarnastega

Hinnamuutus

Aclaris Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

504.58% tõus

12 kuu keskmine prognoos

Keskmine 9.25 USD  504.58%

Kõrge 15 USD

Madal 2 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Aclaris Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

4

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.495 / 1.62Toetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Aclaris Therapeutics Inc

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.